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Musculoskeletal tumours throughout history and beyond:
Clinical features, imaging, staging and biopsy
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Abstract
Background: Over the last century, there has been a remarkable development in the study of bone and soft tissue sarcomas.
This is primarily due to the improved knowledge of the nature of these lesions and the improved imaging technology. In
literature there are many protocols that are being used and all of them have reported various advantages and disadvantages
of each technique used. However, there is no set guideline and whatever has been proposed has been developed on the
basis of the experience of diﬀerent centres and diﬀerent surgeons.
Objective: The current systematic review was planned to thoroughly evaluate the levels of evidence on which we base decisions for surgical management of lower extremity bone tumours.
Methods: The review included descriptive studies published in the English language. Studies included case reports, case
series and experiences of diﬀerent centres for the surgical management of lower extremity bone tumours. Articles reporting
all levels of evidence – Level I to V – were included. PubMed, ERIC, MEDLINE, EMBASE and Cochrane Reviews databases from
2002 to 2012 were searched.
Results: Information was gathered and thoroughly studied from 63 articles. There were no Level I studies, 2(3.2%) Level II
studies, 47(74.6%) Level III, and the remaining 14(22.2%) studies were Level IV and Level V.
Conclusion: Sarcomas are rarely occurring neoplastic conditions which are present in all age groups but commonly aﬀect
young age population. Most are asymptomatic but can present with pain or pathological fracture. These lesions are commonly diagnosed with plain radiographs. CT scan and MRI may be used to delineate anatomy and to quantify the extent of
soft tissue involvement. Various advantages and disadvantages associated with each aspect in the management of patients
starting from the basic history-taking, physical examination, imaging, biopsy principles, peri-operative laboratory work-up
and staging of the cancer were studied. Treatment ranges from conservative to en-block resection including extended
curettage. Aggressive tumours should be closely followed up for recurrence and metastasis.
Keywords: Musculoskeletal, Orthopaedic, Tumour, History, Staging.
(JPMA 70: 1605; 2020) DOI: https://doi.org/10.5455/JPMA.11954

Introduction
Sarcomas have been found in literature since the time of
the ancient Egyptians in 1500 BC.1 Galen was the ﬁrst to use
the term “sarcoma” which comes from Sarx (ﬂesh), and he
distinguished them from cancers, that these arise in the
ﬂesh.2,3 Till the 1800s there was no progress and the
mainstay of treatment was amputation.
The ﬁrst case series of bone tumours was published by
Samuel Gross in 1879 after the advent of X-rays and
microscope. He published 165 cases comrising of giant cell
tumours, osteosarcoma and Ewing’s and he gave both
clinical and pathological views.4 In 1900s James Ewing and
Ernest Codman were the ones who formed the ﬁrst
orthopaedic tumour registry. Ernest Codman is known for
what he called the Codman’s triangle.5,6 Ewing was a
pathologist who suﬀered from chronic osteomyelitis, which
was never cured.7 William Coley was a physician and is
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considered the pioneer of using radiation, immunotherapy
and chemotherapy for cancers.8 He used Coley’s reagent,
which was a bacterial solution, which he injected and
found that the sarcoma regressed with that. His daughter
formed an institute after that and the research of
immunotherapy developed from there.8
Over the last century, there has been a remarkable
development in the study of bone and soft tissue sarcomas.
This is primarily due to the improved knowledge of the
nature of these lesions, improved imaging technology –
previously it was just X-rays that were used to base the
ﬁndings upon and skipped lesions as well as neurovascular
status could not be identiﬁed. Hence a wide margin was
not a plausible option. But now with improved imaging
technology, such as magnetic resonance imaging (MRI),
accurate knowledge of the extent of the tumour is
possible.9,10 Biopsy techniques have also improved and
there is better pathological recognition before starting the
treatment.11 The most impact that has been made in
survival has been the advent of chemotherapy because
previously when there was only surgery available for bone
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sarcomas, more than 80% patients used to die. The 5-year
survival rate was <20%. But with the advent of
chemotherapy, it has gone up to 78-80% and it has led to
the increased survival in these patients and has helped in
limb sparing surgery.12 The modern modular
endoprosthesis has allowed the surgeons to salvage the
limb even in large tumour resections. Allograft banks have
also helped in reconstruction and limb-saving surgeries.13
The current systematic review included studies from 2002
to 2012 about the levels of evidence on which health
professionals base decisions for surgical management of
lower extremity bone tumours. PubMed, Education
Resources Information Centre (ERIC), MEDLINE, EMBASE
and Cochrane Review databases were searched and
resulted in 63 articles that were thoroughly scanned. There
were no Level I studies, 2(3.2%) Level II studies, 47(74.6%)
Level III, and the remaining 14(22.2%) studies were Level IV
and Level V. These included case reports, case series and
experiences of diﬀerent centres. It was evident that there
are many protocols being used and all of them have been
reported to have lots of advantages and disadvantages.14
However, there is no set guideline and whatever has been
developed has been on the basis of the experience of
diﬀerent centres and diﬀerent surgeons.
Soft Tissue Sarcoma: Soft tissue and bone sarcomas are very
rare and heterogeneous group of tumours. They are <1%
of all adult malignancies and <15% of all paediatric
malignancies.15
Risk factors include radiation therapy, especially in
childhood, exposure to chemicals such as vinyl chloride
which is used in the plastic industry and arsenic,
immunodeﬁciency, prior injury and chronic tissue irritation
such as burns and scars, Paget’s disease, bone infarcts,
neuroﬁbromatosis itself and various cancer syndromes like
the hereditary retinoblastoma, Li Fraumeni syndrome and
Gardner’s syndrome.16
Sarcomas originate from mesoderm and are classiﬁed
according to the adult tissue that they resemble. If they
come from the muscle, they are rahbdomyo-sarcoma etc.
and if they are bone sarcoma, they are classiﬁed according
to the type of matrix they produce, like osteoid-producing
ones are osteosarcomas and chondroid-producing are
chondrosarcomas. With regard to grading, it is low,
intermediate and high based on tumour morphology,
extent of pleomorphism, atypia, mitosis and necrosis. Some
use a 4-tier system as GI, II, III, IV but what needs to be
understood is that the grade presents biological
aggressiveness and correlates with the likelihood of
metastasis. So a high-grade lesion has a higher chance of
metastasising and it also has a high chance of being locally
Vol. 70, No. 9, September 2020

Musculoskeletal tumours throughout history and beyond: Clinical ..

aggressive and progressing quickly with respect to time.17
Usually sarcomas grow centrifugally and the periphery is
usually the least mature and they are enclosed by a reactive
zone, which is the pseudocapsule, and this consists of
compressed tumour cells, ﬁbro-vascular zone of reactive
tissue and a variable inﬂammatory component. Sometimes
there is local invasion of this capsule and there are “skip
metastases” found locally. Sarcomas usually respect
anatomical borders and they take the path of least
resistance and grow within the anatomical compartment
in which they arise. But later if the tumour is very
aggressive, it can violate the walls. Yet joint involvement
usually is rare.16,18
Metastatic pattern usually involves dissemination almost
exclusively through the blood. Lymphatic metastasis is
negligible. Metastasis to lungs is the most common
site.16,18,19
Assessment of Patient: Age of the patient can be an
extremely important determinant in some lesions in which
the age range of occurrence may be quite narrow. For
example, malignant osseous lesions in patients under one
year of age are usually metastatic neuroblastoma.20
Malignant osseous lesions in those aged 1-30 years are
usually osteosarcoma or Ewing's sarcoma.16 Malignant
osseous lesions in the 30-60-year range most commonly
will be either chondrosarcoma, primary lymphoma or
malignant ﬁbrous histiocytoma, while malignant lesions in
those aged >50 years most commonly will be due to
metastatic disease or multiple myeloma.21,22
Pain in bone sarcoma is initially activity-related and usually
it becomes progressive and at rest or at night. Soft tissue
sarcomas are usually painless and the patient presents with
mass, except for nerve sheath tumours, which may come
with pain and neurological signs.
Physical examination should include general health, and,
for the mass itself, the size, location, shape, consistency,
mobility, tenderness, local temperature, change with
position should be noted, and the same should be the case
with atrophy of surrounding musculature, any neurological
or vascular deﬁcits, and systemic signs of other diseases like
cafe-au-lait spots for neuroﬁbromatosis. Also of importance
is the examination of regional lymph nodes.17,23
Radiological Assessment
Plain X-ray: Initially, a musculoskeletal tumour should be
simply imaged with a plain ﬁlm that remains the most
reliable imaging method for the assessment of both
biological activity and probable histological diagnosis of
an osseous lesion.10 Points to remember when assessing
an X-ray include solitary/multiple lesions; location of the
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bone involved; margins of the lesion well or ill-deﬁned; the
cortex eroded or destroyed; any peri-osteal new-bone
formation; and the possibility of the tumour extending into
the soft tissues.
According to location and age, diﬀerential diagnosis for
epiphyseal lesions usually within the age range 10-15 years
are generally chondroblastoma,24 while in age range 30-40,
they are usually giant cell tumours.25 Similarly, for
diaphyseal lesions in the younger age group, it is Ewing’s
sarcoma or ﬁbrous dysplasia, and in the adults, it is usually
lymphomas.21 For spine lesions in patients >40 years,
metastasis and multiple myeloma are at the top of the list.26
In young patients there are more benign tumours like
histocytosis and haemangioma.27
Patterns of bone destruction usually range from
geographical to moth-eaten to permeative with increasing
trend towards more aggressive tumours. Geographical
lesions are probably locally invading tumours. Moth-eaten
bone is found in myeloma and metastatic disease and
signiﬁes an increased disease burden.26 Permeative is
locally aggressive and malignant tumour like Ewing’s and
osteosarcoma.16
Peri-osteal reactions are graded from solid in benign
tumours with thicker peri-osteum to onion peel
appearance representing aggressive lesion.27 Quickly
growing tumour stretches the Sharpey’s ﬁbres, those that
attach the peri-osteum to the bone. They stretch to such a
degree that they become perpendicular to the bone, and
then, when ossiﬁcation takes place, lead to sunburst time
of appearance or speculated appearance. More malignant
and aggressive tumours don’t have time for ossiﬁcation,
and results in a Codman’s triangle formation.5 This happens
so quickly that the entire peri-osteum lifts up and it does
not get time to ossify, and what one sees is a rim of the
thing. So it is not a complete triangle.
Then the matrix that the bone lays down, usually the
cartilaginous tumours, results in a chrondroid matrix, which
usually appears ﬂuﬀy like popcorn. The osteoid matrix is
more dense and the tumour usually remains inside the
bone.28,29
Computed Tomography (CT) Scan
It is used for assessing ossiﬁcation and integrity of cortex;
pathological fractures; localising the nidus of osteoid
osteoma; detecting whether a thin rim of reactive bone is
around an ABC; evaluating calciﬁcation in a suspected
cartilaginous lesion and endosteal cortical erosion in a
suspected chondrosarcoma; surgical planning and custommade implant manufacturing; and pulmonary metastasis.
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A CT scan is the only tool if the MRI is prohibited.
MRI: It has revolutionised bone sarcoma treatment.
Beneﬁts include calculation of the size and extent,
intramedullary and extra-medullary spread and
neurovascular structures, and it helps in a diagnosis, lipoma
and haemangioma, without biopsy. Any soft tissue
neoplasm deep to the fascia or >5cm is malignant until
proven otherwise.10,30
Bone Scan: A bone scan is helpful in determining multiple
lesions or skeletal metastases with limited sensitivity and
speciﬁcity. It would miss intramedullary small skip lesions
and it may be false negative (FN) in multiple myeloma and
some cases of renal cell carcinoma.
Positron emission tomography (PET) Scan: The PET scan
is the latest talk of the town.31 It checks the distribution of
positron-emitting radioisotopes, which are linked to
biologically active molecules. The ﬂuorodeoxyglucose
(FDG) used is an analogue of glucose that becomes
trapped in malignant cells and in proportion to their
respective rate of glycolysis/activity. This results in
providing a non-invasive three-dimensional (3D)
visualisation of anatomy, if combined with CT/MRI, as well
as a quantitative assessment of the physiology of the
tumour. Another area of help is to diﬀerentiate between
post-surgical or post-radiation changes and recurrence of
tumour, which the MRI cannot. Viable tumour cells will
actively light up in a PET scan.
Blood Tests: Albumin and total lymphocyte count (TLC)
are used for assessing nutritional status of the patient
which is directly associated with wound healing and
wound dehiscence risk. Complete blood count (CBC) is the
baseline to rule out infection and to check if leukaemia is
suspected. Erythrocyte sedimentation rate (ESR) is elevated
in infections, metastatic carcinoma and other tumours as
well. If multiple myeloma is suspected, then the options are
serum protein electrophoresis, prostate-speciﬁc antigen
(PSA) for prostate carcinoma, calcium, alkaline phosphatase
and parathyroid hormone (PTH) for metastatic or metabolic
bone disease, and blood urea nitrogen (BUN) and
creatinine if renal tumours are suspected. All the
investigations should be completed before a biopsy. The
diﬀerential diagnosis, extent of the lesion and potential
resectability can aﬀect the type of biopsy.32
Biopsy: Fine needle aspiration cytology (FNAC) is very costeﬀective and can be done using a simple 10cc needle. It is
up to 90% accurate at determining malignancy. It has fewer
complications and may be good for obese patients or for
tumours near neurovascular structure – if it is done
radiologically-guided. The disadvantages are that it has
very small sample size and requires a very expert and
J Pak Med Assoc
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dedicated pathologist, and one can only do cytology. It is
good for metastatic lesions and sampling lymph nodes
because you just need to identify if the lesion is malignant.
Core needle biopsy gets a little tissue and is also costeﬀective. Core needle biopsy has a yield of up to 84-98%
and accuracy of 81%. Accuracy further improves if it is done
with image guidance.33
Incisional biopsy is the gold standard. It can employ frozen
section to conﬁrm that adequate tissue is sent. Even for
some tumours one can plan surgery in one go. If clinically
a giant cell tumour is suspected, a frozen section is sent to
get conﬁrmation and to do the surgery at the same stage.
Contamination can occur which can compromise deﬁnite
resection, especially if done by an inexperienced surgeon
in the ﬁeld of orthopaedic oncology. Cost is another issue.
To overcome that, studies reported that out-patient clinicbased biopsy is safe, with diagnostic accuracy of 95.5% with
low morbidity.34,35
Excisional biopsy is for small subcutaneous masses <3cm
which are unlikely to be malignant upon radiological
examination. For larger deeper lesions, excisional biopsy is
safe if the MRI appearance is diagnostic and conﬁrmatory
of lipomas.36
Biopsy principles: The smallest of longitudinal incisions is
needed. When doing a deep incision, like piercing the
fascia, it should go through a single muscle compartment
and should not contaminate an inter-muscular plane.37
Demarcation lines and the principle of biopsy can be seen
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on the ﬁgure (ﬁgure).
A knife or curette is used while ensuring it is sharp. If going
for bone holes, they should be oblong so that one can
increase the length of the bone hole, but should not
increase its diameter, as diameter aﬀects stability. The
corners are kept round to avoid stress points.
One should always obtain enough tissue and frozen section
should be sent. If a tourniquet is used, it should not
exsanguinate the limb. Any haematoma should be drained
and haemostasis secured because the haematoma will be
considered contaminated. Drains are used only when
necessary. Drain tract is treated just like biopsy tract and
has to be excised with it, and, as such, it should be in line
with the incision.38,39 It is critical that biopsy should
preferably be done by the primary oncology surgeon who
will do the deﬁnite procedure, otherwise limb-saving
results will be suboptimal. Just getting the diagnosis is not
the key.
Staging of Musculoskeletal Tumour: The Enneking
staging system is the one that is accepted by the
Musculoskeletal Tumour Society.40 This deﬁnes benign
tumours into latent, active and aggressive. Latent tumours
are the ones that remain static or heal spontaneously such
as lipomas or non-ossifying ﬁbromas. Active tumours are
those that progress with growth, but are limited by natural
barriers as they don’t grow out of the bone. Examples are
angiolipoma and aneurysmal bone cyst. The aggressive
tumours are the one ones that are progressive by growth,

Figure: 14-year-old boy with osteosarcoma over right buttock region, biopsied with large transverse incision. Clinical photograph with the patient in left lateral position, showing a
large transverse incision (14 cm) just above the right buttock region done for an incisional biopsy for a suspected sarcoma (A). Right photograph showing the large incision
(arrow) we were forced to do to include the previous large scar as well, which compromised the blood supply to the skin flap leading to marginal necrosis and second
debridement and excision of necrotic skin.
Asterisks showing L4 & L5 vertebrae levels..
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invasive and not limited by natural barriers, like the giant
cell tumour or aggressive ﬁbromatosis.
Enneking staging of malignant tumours is based on
histological grade, low or high, location, intracompartmental or extra-compartmental, and whether
metastasis is present. It includes stage-I tumours, intra and
extra-compartmental with no metastasis.40
Similarly, the American Joint Committee on Cancer Staging
system is the standard tumour, node and metastases (TNM)
classiﬁcation that covers all types of tumours. For soft tissue
sarcomas, the T1 and T2 are according to the cut-oﬀ of 5cm.
For the bone tumours, the T1 and T2 cut-oﬀ is 8cm.38,41

Conclusion
Bone and soft tissue sarcomas are frequently occurring
neoplastic conditions which are present in all age groups,
but commonly aﬀect young population. Most are
asymptomatic, but can present with pain or pathological
fracture. These lesions are commonly diagnosed with plain
radiographs. CT scan and MRI may be used to delineate
anatomy and the extent of soft tissue involvement.
Following the clinical, laboratory and radiological work-up,
biopsy is the major mode of assessment to identify and
lead to a deﬁnitive diagnosis. Based on the results, a
directed approach is followed by a treatment plan which is
surgery in most cases, and the decision is made with regard
to the type of surgery to be planned.
Disclaimer: None.
Conﬂict of Interest: None.
Source of Funding: None.
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